173 related articles for article (PubMed ID: 27867431)
1. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Mossell J; Goldman JA; Barken D; Alexander RV
Open Rheumatol J; 2016; 10():71-80. PubMed ID: 27867431
[TBL] [Abstract][Full Text] [Related]
2. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
O'Malley T; Xie F; Su Y; Clinton C; Zack DJ; Haechung C; Grabner M; Curtis JR
J Manag Care Spec Pharm; 2022 Sep; 28(9):1021-1032. PubMed ID: 35775579
[No Abstract] [Full Text] [Related]
3. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
[TBL] [Abstract][Full Text] [Related]
4. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.
Liang E; Taylor M; McMahon M
Lupus Sci Med; 2020; 7(1):e000345. PubMed ID: 32231785
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Lupus Erythematosus Patients With a Negative Antinuclear Antibody Meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus.
Tarazi M; Gaffney RG; Kushner CJ; Chakka S; Werth VP
Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1404-1409. PubMed ID: 31058462
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.
Mosca M; Costenbader KH; Johnson SR; Lorenzoni V; Sebastiani GD; Hoyer BF; Navarra S; Bonfa E; Ramsey-Goldman R; Medina-Rosas J; Piga M; Tani C; Tedeschi SK; Dörner T; Aringer M; Touma Z
Arthritis Rheumatol; 2019 Jan; 71(1):91-98. PubMed ID: 30035365
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus.
Tao JJ; Hiraki LT; Levy DM; Silverman ED
J Rheumatol; 2019 Jul; 46(7):731-738. PubMed ID: 30770510
[TBL] [Abstract][Full Text] [Related]
8. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.
Ramsey-Goldman R; Alexander RV; Conklin J; Arriens C; Narain S; Massarotti EM; Wallace DJ; Collins CE; Saxena A; Putterman C; Brady K; Kalunian KC; Weinstein A
ACR Open Rheumatol; 2021 Feb; 3(2):116-123. PubMed ID: 33538130
[TBL] [Abstract][Full Text] [Related]
9. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).
Lamichhane D; Weinstein A
Lupus; 2016 Aug; 25(9):1050-3. PubMed ID: 26911153
[TBL] [Abstract][Full Text] [Related]
10. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
Hui-Yuen JS; Gartshteyn Y; Ma M; O'Malley T; Conklin J; Eichenfield AH; Imundo LF; Dervieux T; Askanase AD
Lupus; 2018 Dec; 27(14):2262-2268. PubMed ID: 30376789
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC).
Oku K; Atsumi T; Akiyama Y; Amano H; Azuma N; Bohgaki T; Asanuma YF; Horita T; Hosoya T; Ichinose K; Kato M; Katsumata Y; Kawaguchi Y; Kawakami A; Koga T; Kohsaka H; Kondo Y; Kubo K; Kuwana M; Mimori A; Mimori T; Mimura T; Murakami K; Nakano K; Nakayamada S; Ogishima H; Ohmura K; Saito K; Sano H; Shibuya M; Takahashi Y; Takasaki Y; Takeuchi T; Tamura N; Tanaka Y; Tsuboi H; Tsunoda S; Yukawa N; Yamakawa N; Yamamoto K; Sumida T
Mod Rheumatol; 2018 Jul; 28(4):642-648. PubMed ID: 29120258
[TBL] [Abstract][Full Text] [Related]
12. Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE).
Tiao J; Feng R; Carr K; Okawa J; Werth VP
J Am Acad Dermatol; 2016 May; 74(5):862-9. PubMed ID: 26897388
[TBL] [Abstract][Full Text] [Related]
13. Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-analysis.
Hartman EAR; van Royen-Kerkhof A; Jacobs JWG; Welsing PMJ; Fritsch-Stork RDE
Autoimmun Rev; 2018 Mar; 17(3):316-322. PubMed ID: 29366725
[TBL] [Abstract][Full Text] [Related]
14. The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus.
Flynn A; Gilhooley E; O'Shea F; Wynne B
Clin Rheumatol; 2018 Mar; 37(3):817-818. PubMed ID: 29392510
[TBL] [Abstract][Full Text] [Related]
15. Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort.
Inês L; Silva C; Galindo M; López-Longo FJ; Terroso G; Romão VC; Rúa-Figueroa I; Santos MJ; Pego-Reigosa JM; Nero P; Cerqueira M; Duarte C; Miranda LC; Bernardes M; Gonçalves MJ; Mouriño-Rodriguez C; Araújo F; Raposo A; Barcelos A; Couto M; Abreu P; Otón-Sanchez T; Macieira C; Ramos F; Branco JC; Silva JA; Canhão H; Calvo-Alén J; ;
Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1180-5. PubMed ID: 25581417
[TBL] [Abstract][Full Text] [Related]
16. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.
Alexander RV; Rey DS; Conklin J; Domingues V; Ahmed M; Qureshi J; Weinstein A
Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253650
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
Wallace DJ; Silverman SL; Conklin J; Barken D; Dervieux T
Lupus Sci Med; 2016; 3(1):e000127. PubMed ID: 26870391
[TBL] [Abstract][Full Text] [Related]
18. Cell-bound complement activation products in SLE.
Ramsey-Goldman R; Li J; Dervieux T; Alexander RV
Lupus Sci Med; 2017; 4(1):e000236. PubMed ID: 29214038
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.
Wirestam L; Schierbeck H; Skogh T; Gunnarsson I; Ottosson L; Erlandsson-Harris H; Wetterö J; Sjöwall C
Arthritis Res Ther; 2015 Nov; 17():338. PubMed ID: 26596890
[TBL] [Abstract][Full Text] [Related]
20. Detection of anti-nuclear antibody by immunofluorescence assay and enzyme immunoassay in childhood systemic lupus erythematosus: experience from Bangladesh.
Dipti TR; Azam MS; Sattar MH; Rahman SA
Int J Rheum Dis; 2012 Feb; 15(1):121-5. PubMed ID: 22324956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
